The safety of methadone hydrochloride

Expert Opinion on Drug Safety

Volumn 7, Issue 1, 2008, Pages 5-8

  Swegle, John M ^a   Wensel, David D ^b  

^a Mercy Family Medicine Residency Program   (United States)

^b Mercy Medical Center North Iowa   (United States)

Author keywords

Adverse events; Methadone; Safety

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A4 INHIBITOR; ENZYME INHIBITOR; METHADONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OPIATE; OPIATE RECEPTOR; SEDATIVE AGENT; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ASTHMA; BIOTRANSFORMATION; BREATHING DISORDER; CENTRAL SLEEP APNEA SYNDROME; COMPARTMENT MODEL; CONTINUOUS INFUSION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG FATALITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; EDITORIAL; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; NEUROPATHIC PAIN; NOCICEPTION; OBESITY; QT PROLONGATION; RESPIRATION DEPRESSION; RISK FACTOR; SEDATION; SIDE EFFECT; TORSADE DES POINTES;

ANIMALS; HUMANS; METHADONE; OPIOID-RELATED DISORDERS; PAIN; RESPIRATORY INSUFFICIENCY;

EID: 38949208213     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.1.5     Document Type: Editorial

References (24)

1. Nicholson AB. Methadone for cancer pain. Cochrane Database Syst Rev 2004;2:CD003971
2. Toombs JD, Kral L. Methadone treatment for pain states. Am Fam Physician 2005;71:1353-8
3. Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother 2005;19:13-24
4. Ferrari A, Rosasio Coccia CP, Bertolini A, et al. Methadone - metabolism, pharmacokinetics, and interactions. Pharmacol Res 2004;50:551-9
5. Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. J Palliat Med 2002;5:127-38
6. Berdine HJ, Nesbit SA. Equianalgesic dosing of opioids. J Pain Palliat Care Pharmacother 2006;20:79-84
7. Manfredi PL, Borsook D, Chandler SW, Payne R. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations. Pain 1997;70:99-101
8. Santiago-Palms J, Khojainova N, et al. Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl. Cancer 2001;92:1919-25
9. Manfredi PL, Houde RW. Prescribing methadone, a unique analgesic. J Support Oncol 2003;1:216-20
10. Zimmerman C, Seccareccia D, Booth CM, Cottrell W. Rotation to methadone after opioid dose escalation: how should individualization of dosing occur? J Pain Palliat Care Pharmacother 2005;19:25-31
11. Yennurajalingam S, Braiteh F, Bruera E. Pain and terminal delirium research in the elderly. Clin Geriatr Med 2005;21:93-119
12. Crettol S, Deglon JJ, Besson J, et al. ABCBI and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006;80:668-81
13. Kharasch ED, Hoffer C, Whittington D, Scheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004;76:250-69
14. Crettol S, Deglon JJ, Besson J, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005;78:593-604
15. Brown R, Kraus C, Fleming M, Reddy S. Methadone: applied pharmacology and use as adjunctive treatment in chronic pain. Postgrad Med J 2004;80:654-9
16. Wysowski DK: Surveillance of prescription drug-related mortality using death certificate data. Drug Saf 2007;30:533-40
17. Paulozzi LJ, Budnitz DS, Yongli X. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 2006;15:618-27
18. Food and Drug Administration alert; 2006. Available at URL: http://www.fda.gov/cder/drug/unfopage/methadone/default/htm
19. Dolophine® Hydrochloride (methadone hydrochloride tablets, USP), Roxane Laboratories, Inc. Columbus, Ohio, October 2006
20. Wang D, Teichtahl H. Opioids, sleep architecture and sleep-disordered breathing Sleep Med Rev 2007;11:35-46
21. Walker JM, Farney RJ, Rhondeau SM. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med 2007;15:455-61
22. Ehret GB, Desmeules JA, Broers B. Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lesions learned for pharmacology. Expert Opin Drug Saf 2007;6:289-303
23. Kornick CA, Kilborn MJ, Santiago-Palma J, et al. QTc interval prolongation associated with intravenous methadone. Pain 2003;105:499-506
24. Eap CB, Crettol S, Rougier JS, et al. Stereoselective block of hERG channel by S-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 2007;81:719-28